
Maybe time to blow the dust off here?
Interim Results
Financial Summary
· Revenue of $56.8m (H1 2012: $56.1m)
· Gross profit of $20.2m (H1 2012: $19.2m) - an improved gross margin of 35.6% (H1 2012: 34.2%)
· Gross operating profit of $0.08m (H1 2012: $0.85m)(being operating losses excluding amortisation of intangibles)
· Net loss for the period was $1.7m (H1 2012: $0.3m loss) after net finance costs of $0.5m (H1 2012: $0.9m net finance income) comprising predominantly of adverse foreign currency movements
· Basic loss per share of 0.32¢ (H1 2012: 0.01¢ loss)
· As at 30 June 2013, the Group had cash and cash equivalents and deposits of $44.5m (31 December 2012: $46.2m; 30 June 2012: $42.3m)
Operational Summary
· Telecom division:
o Continued to grow compared with H1 2012 and contributed 55% of the Group's total sales
o T-Metro 8000 platform and Edge Genie service management solution continue to increase contribution to revenues and profits
o Gained additional customers for the new T-Metro 8006 cloud aggregator platform
o Part of consortium awarded long-term contract by Israeli Electricity Corporation to build and roll-out a fiber optic network in Israel together with Cisco Systems
o Completed sale of legacy business to a management led buy-out and re-integrated one product line back into the division's portfolio
· Medical division:
o Continued year-on-year growth despite brief stall in Q2 2013 and contributed 45% of total sales
o As stated in trading update of 6 June 2013, the failure of third-parties to supply components on time delayed fulfilment of orders
o Diagnostics business:
§ Improved performance in sales and gross profit with 50 closed system machines sold in the first half of 2013
§ Revenues from sale of Eclectica reagents have already reached 74% of total achieved in 2012
§ Regular sales in major emerging markets, including China
o Sterilisation business:
§ Over 100 units operating
§ Process to clear back orders in sterilisation business well underway
§ Patent received for Integrated Sterilizer and Shredder ("ISS") is being registered in several markets
o Distribution business:
§ Trading has returned to normal after tight credit control forced the Group to stop supplies to certain major customers resulting in lower contribution to sales, as set out in trading update in June
Dr Zvi Marom, Chief Executive Officer of BATM, said:
"Despite the challenging trading conditions in many markets, we are pleased to report that BATM grew in both Telecom and Medical divisions in the first half of the year. The Telecom division continued to win new customers for its new flagship products and the main growth engine of the Medical division, the diagnostics business, continued to progress with regular sales in the major emerging markets including China.
"Looking ahead, the Telecom division is making good progress as revenues from the T-Metro 8000 platform continue to grow. The issues highlighted in our trading update in June are behind us with orders in the Medical division having normalised and are now being delivered according to our expectations. Also, in the Medical division, reliance on the distribution business continues to reduce as there is an increased contribution from the diagnostics business.
"As a result, for the full year 2013, the Group expects to achieve higher revenues and EBITDA than for 2012."